Replies to post #101009 on Elite Pharmaceuticals Inc (ELTP)

[lasers]

Waiting now for the USPTO entry to allow viewing of $ELTP new PATENT 8,703,186 on USPTO Portal/Pair website.

[Couch]

Elite's 3rd US ART Patent will be official on April 22, 2014. : Patent 8,703,186

Here is what NEW INVESTORS Need to Understand. Read and Enjoy $$$$$$$

http://seekingalpha.com/instablog/4199131-couch/1941422-elite-pharmaceuticals-eltp-intellectual-property-ip-and-the-right-to-devise-a-better-pain-killer

It is when you understand the immense financial value of Elite's patented Intellectual Property (IP) along with the aforementioned push to curb the nations' prescription abuse epidemic and depending on how Congress and the FDA move, it would seem Elite could easily be in the midst of the Perfect Storm that is already brewing in the abuse deterrent space.

Elite has previously been given the green light to commence Ph3 trials with their signature once daily oxycodone/naltrexone product. Should Elite be able to pass Ph3 trails, this would be a Game Changer in and of itself. However, when you consider Elite's IP rights for their patented Abuse Resistant Technology (ART), its licensing potential, and the ability to put out multiple abuse resistant products, generic and branded, then the possibilities become absolutely staggering. This staggering possibility is better understood when you realize that shares bought now before trials begin have the real potential to set one up for a really nice financial windfall within the next few years. After all, Elite has technology that is going to give Purdue and Pfizer a run for their money in the abuse deterrent/resistant opioid space.

Date Transaction Description
04-03-2014 Email Notification
04-02-2014 Issue Notification Mailed
03-20-2014 Dispatch to FDC
02-25-2014 Supplemental Papers - Oath or Declaration
03-19-2014 Application Is Considered Ready for Issue